USPTO serial 79295799
VERITAS IN SILICO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 20, 2022
- Examiner
- OSGOOD, KRYSTINA E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VERITAS IN SILICO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, namely chemicals for use in medical industry and medical science; small molecule compounds as chemicals for use in medical science and medical industry; nucleic acids for laboratory use excluding the use in industrial chemistry, other than for medical or veterinary purposes; nucleic acid chemical reagents excluding the use in research or development in industrial chemistry, other than for medical or veterinary purposes; reagents and assays for use in scientific, medical or drug discovery research; reagents for chemical analyses, excluding the use in research or development in industrial chemistry, other than for medical or veterinary purposes; reagents for nucleic acid isolation and purification for medical and drug discovery research purposes; reagents for nucleic acid synthesis and analysis for medical and drug discovery research purposes; diagnostic preparations and assay samples for medical and drug discovery research, clinical research, and laboratory use, other than for medical or veterinary purposes; proteins in raw material form and enzymes for scientific and medical research purposes; cells for research or scientific purposes; nucleic acid, namely, DNA deoxyribonucleic acids for laboratory use; nucleic acid, namely, RNA ribonucleic acids for laboratory use; antibodies, namely, antibody reagents for research use, other than for medical or veterinary purposes; artificial sweeteners; raw materials, namely, unprocessed plastics in all forms; none of the foregoing for use in research or development in industrial chemistry | ACTIVE | — |
| 005 | Pharmaceutical preparations targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; reagent paper for medical purposes; pharmaceutical preparations targeting messenger RNA or other types of RNA, other than for agricultural purposes for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; drugs for medical purposes, targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; biological preparations for medical purposes, targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; nucleic acid sequences for medical and veterinary purposes; cells for medical purposes; blood for medical purposes; diagnostic and therapeutic antibodies for medical purposes; vaccines; enzyme inhibitors, only for medical or veterinary purposes; medical assay preparations for therapeutic or diagnostic purposes; medical diagnostic reagents; reagents for medical purposes; reagents for extracting nucleic acids, only for medical or veterinary diagnostic purposes; pharmaceutical preparations containing nucleic acids, targeting messenger RNA or other types of RNA for the treatment of autoimmune, autoinflammatory diseases, bacterial infections, behavioral and mental disorders, blood diseases, chromosome disorders, congenital and genetic diseases, connective tissue diseases, digestive diseases, ear diseases, nose diseases, throat diseases, endocrine diseases, environmental diseases, eye diseases, female reproductive diseases, fungal infections, heart diseases, hereditary cancer syndromes, immune system diseases, kidney and urinary diseases, lung diseases, male reproductive diseases, metabolic disorders, mouth diseases, musculoskeletal diseases, myelodysplastic syndromes, nervous system diseases, newborn screening, nutritional diseases, parasitic diseases, rare cancers, rare diseases, skin diseases and viral infections; reagents for detection, identification, analysis and quantification of nucleic acids for pharmaceutical and diagnostic medical purposes; enzymes for medical purposes; lacteal flour for babies; dietary supplements for humans; dietetic foods in liquid form adapted for medical purposes; dietetic foods adapted for medical purposes; beverages, namely, dietetic foods in the form of liquid for babies; food for babies; dietary supplements for animals | ACTIVE | — |
| 040 | Custom manufacturing of pharmaceuticals for others; custom synthesis in the nature of custom manufacturing of nucleic acids for others for use in medicines and pharmaceutical preparations; custom extraction, purification, and synthesis, namely, custom manufacturing of pharmaceuticals for others by utilizing genome editing or gene editing technology; custom synthesis in the nature of custom manufacturing of chemical compounds for others for use in medicines and pharmaceutical preparations; custom synthesis in the nature of custom manufacturing of chemical compounds for others; providing material treatment information; printing | ACTIVE | — |
| 041 | Educational and instruction services, namely, organizing events for educational and teaching purposes relating to arts, crafts, sports and general knowledge; teaching in the field of drug discovery and development; educating at universities and graduate schools; arranging, conducting and organization of seminars; arranging, conducting and organization of symposiums, lecture meetings, workshops and study groups; arranging, conducting and organization of educational seminars, symposiums, lecture meetings, workshops and study groups in the field of drug discovery and development; providing online non-downloadable electronic publications in the nature of magazines, newsletters, journals and books in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicine, chemicals and engineering; reference libraries of literature and documentary records; book rental; providing online music, sound recordings, videos featuring information and instruction on nucleic acids, pharmaceuticals, drug discovery and development, medicine, chemicals and engineering, images and character text information, non-downloadable; educational services in the nature of providing exhibits of academic materials in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicine, chemicals and engineering; art exhibitions; publication of books; movie theatre presentations, namely, movie showing and movie film production and distribution; production of videotape film in the field of education, culture, entertainment or sports, not for movies or television programs and not for advertising or publicity | ACTIVE | — |
| 042 | Custom design of chemical reagents and biological assays for use in medicines and engineering design services, not for advertising; development of pharmaceutical preparations and medicines; computer software design, computer programming, and maintenance of computer software for use in RNA targeted drug discovery and development; designing, programming and maintenance of computer software having artificial intelligence functionality for use in RNA targeted drug discovery and development; computer software design, computer programming, and maintenance of computer software for use in scientific and technical analysis of data from artificial intelligence for use in RNA targeted drug discovery and development; computer software design, computer programming, and maintenance of computer software for use in analysis, testing, screening, designing, development or research on nucleic acids, pharmaceuticals or chemicals for use in medicines for use in RNA targeted drug discovery and development; computer software design, computer programming, and maintenance of computer software for use in drug discovery screening; computer software design, computer programming, and maintenance of computer software for use in genome research or treatments, pharmaceutical preparations for RNA targeted drug discovery and development; technological advice relating to computers, automobiles and other industrial machines requiring highly specialized knowledge, skills and experiences for proper operation, namely, computer technology consultancy and industrial machine part design consulting for use in RNA targeted drug discovery and development; scientific research, testing and analysis in the field of nucleic acids, pharmaceuticals, drug discovery and development, medicines, chemicals and engineering for use in RNA targeted drug discovery and development; quality control assessment services for use in RNA targeted drug discovery and development for others; testing, inspection or research of pharmaceuticals for use in RNA targeted drug discovery and development; providing information and consultancy on testing, inspection or research of pharmaceuticals, chemicals for use in medicines, reagents for use in medicines for use in RNA targeted drug discovery and development; scientific or laboratory testing, inspection or research of nucleic acids, chemicals and pharmaceuticals for drug development and medical research purposes, and providing scientific information and research consultancy relating thereto for use in RNA targeted drug discovery and development; testing or scientific research on biotechnology and providing scientific information and research consultancy relating thereto for use in RNA targeted drug discovery and development; genomic experiments, analyses, research, assays, tests, inspection, detection or verification, namely, scientific genomic analyses, scientific genomic research, custom design and development of biochemical genomic assays, genome amplification and functional and structural analysis of genomes for use in RNA targeted drug discovery and development; scientific research consultancy, advice and providing scientific research information in the field of genomic experiments, analyses, research, assays, tests, inspection, detection or verification for use in RNA targeted drug discovery and development; scientific and technological services, namely, testing, analysis surveying, research or data analysis in the field of biomedicine, genome biology, pharmacogenomics, diagnostics, clinical trials and bioengineering for use in RNA targeted drug discovery and development; research and development of vaccines and medicines; development of pharmaceutical preparations and medicines; conducting clinical trials for pharmaceuticals for use in RNA targeted drug discovery and development for others; rental of computers; providing computer programs on data networks, namely, providing temporary use of non-downloadable computer software for enabling, supporting and accelerating processes of RNA-targeted drug discovery and development for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; providing temporary use of non-downloadable computer software having artificial intelligence functionality on data networks for enabling, supporting and accelerating processes of RNA-targeted drug discovery and development for use in research and development of nucleic acids, pharmaceuticals, medicines and chemicals; providing online non-downloadable computer software for analyzing science and technology data based on artificial intelligence (AI) technology for use in RNA targeted drug discovery and development; providing online non-downloadable computer software for analyzing, testing, screening, designing, developing and researching of nucleic acids, pharmaceuticals and chemicals for use in RNA targeted drug discovery and development; providing online non-downloadable computer software for drug discovery screening; providing online non-downloadable computer software for conducting and accessing genome research and treatments, pharmaceutical preparations for use in RNA targeted drug discovery and development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Veritas In Silico Inc.
- Other trademarks owned by Veritas In Silico Inc.
- Other trademarks owned by Veritas In Silico Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named VERITAS IN SILICO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 20, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Aug 20, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 20, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 20, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 23, 2024 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Nov 25, 2023 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 15, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 22, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 22, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 20, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 11, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 11, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 11, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 11, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 20, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 20, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 14, 2022 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| May 25, 2022 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| May 24, 2022 | APET | ASSIGNED TO PETITION STAFF | — |
| May 10, 2022 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Apr 28, 2022 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Apr 10, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 10, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 5, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 5, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 23, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 23, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 16, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 16, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 16, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 2, 2022 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Feb 8, 2022 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Jan 28, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 20, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 20, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 20, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 24, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 10, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 10, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 10, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 29, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 12, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 12, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 23, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 22, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 21, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 19, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 19, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 15, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |